Related Experiment Video
Updated: Jul 16, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Pharmacokinetics and drug interactions with zonisamide
1Epilepsy Unit, University Division of Cardiovascular and Medical Sciences, Western Infirmary, Glasgow, Scotland, UK. g.j.sills@clinmed.gla.ac.uk
Epilepsia
|February 27, 2007
Summary
Zonisamide, an antiepileptic drug, has minimal drug interactions, making it a safe option for epilepsy patients. It does not affect other epilepsy medications but its clearance is increased by certain drugs.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Neuroscience
Background:
- Polypharmacy is common in epilepsy management, especially for refractory cases.
- Older antiepileptic drugs (AEDs) frequently cause pharmacokinetic interactions via cytochrome P450 (CYP) and uridine glucuronyl transferase enzyme systems.
- Minimizing drug interactions is crucial for effective and safe epilepsy treatment.
Purpose of the Study:
- To evaluate the pharmacokinetic interaction profile of zonisamide with other antiepileptic drugs (AEDs).
- To assess the potential for zonisamide to cause adverse drug interactions in epilepsy patients.
- To determine the suitability of zonisamide as adjunctive therapy in refractory epilepsy.
Main Methods:
- Conducted a series of drug interaction studies.
- Investigated the effect of zonisamide on the steady-state pharmacokinetics of carbamazepine, phenytoin, sodium valproate, and lamotrigine.
- Examined the impact of carbamazepine, phenytoin, and phenobarbital on zonisamide clearance.
Main Results:
- Zonisamide did not affect the steady-state pharmacokinetics of carbamazepine, phenytoin, sodium valproate, or lamotrigine.
- Carbamazepine, phenytoin, and phenobarbital increase zonisamide clearance, potentially requiring dosage adjustments.
- Zonisamide demonstrated no clinically significant interactions with other AEDs, oral contraceptives, or other investigated therapeutic agents.
Conclusions:
- Zonisamide possesses a favorable pharmacokinetic profile with limited drug-drug interactions.
- Zonisamide can be a useful and uncomplicated adjunctive therapy for refractory epilepsy.
- The minimal interaction potential of zonisamide enhances its safety and efficacy in polypharmacy regimens.
Related Concept Videos
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...